| Autor: |
Creaven, Patrick J., Zakrzewski, Sigmund F., Greco, William R., Madajewicz, Stefan, Mittelman, Arnold, Pontes, J. Edson, Karakousis, Constantine, Takita, Hiroshi, Proefrock, April |
| Zdroj: |
Cancer Chemotherapy and Pharmacology; April 1988, Vol. 21 Issue: 2 p122-128, 7p |
| Abstrakt: |
A phase I and pharmacokinetic study of a novel lipid-soluble antifolate, 2,4 diamino-5-adamanty-6-methyl pyrimidine ethane sulfonate (DAMP-ES) has been carried out on two schedules: I—dailyx5; II—24-h continuous infusion. In schedule I, doses of 10–90 mg/m2 per day were evaluated. Dose-limiting toxicity was hematologic, but nausea and vomiting, skin rash, diarrhea, anorexia, alopecia, mucositis, and neurotoxicity were also noted. In schedule II, doses of 192 and 240 mg/m2 were evaluated. Dose-limiting toxicity was neurotoxicity, but hematologic toxicity was also marked. Recommended starting doses for phase II studies are 75 mg/m2 per day for 5 days or 192 mg/m2 by continuous infusion for 24 h. Pharmacokinetic studies indicated a ß-phase plasma half-life of 12.4–24 h and a large and variable volume of distribution. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink